EurekaMag.com logo
+ Site Statistics
References:
53,517,315
Abstracts:
29,339,501
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Azole antifungal agents: emphasis on new triazoles



Azole antifungal agents: emphasis on new triazoles



Antimicrobial Agents and Chemotherapy 32(1): 1-8



The clinical efficacy and toxicity of the azole antifungal agents are discussed, followed by a review of the triazole antifungal agents, in particular fluconazole and itraconazole, focusing on their structure, mechanisms of action, in vitro and in vivo (animal models) antifungal activities and clinical studies.

Accession: 001534346

Download citation: RISBibTeXText

PMID: 2831809

DOI: 10.1128/aac.32.1.1

Download PDF Full Text: Azole antifungal agents: emphasis on new triazoles



Related references

Synergic effects of tacrolimus and azole antifungal agents against azole-resistant Candida albicans strains. Journal of Antimicrobial Chemotherapy 42(6): 747-753, 1998

Synergic effects of tactolimus and azole antifungal agents against azole-resistant Candida albican strains. Journal of Antimicrobial ChemoTherapy 42(6): 747-753, 1999

The combination effects of MDR inhibitors and azole antifungal agents against azole resistant Candida albicans strains. Clinical Infectious Diseases 25(2): 487, 1997

Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrobial Agents and ChemoTherapy 42(2): 241-253, 1998

A single amino acid substitution in the cytochrome P-450 lanosterol 14alpha-demethyalase from azole-resistant Cryptococcus neoformans clinical isolate contributed to resistance to azole antifungal agents. Abstracts of the General Meeting of the American Society for Microbiology 101: 370, 2001

The role of azole antifungal agents for systemic antifungal therapy. Cleveland Clinic Journal of Medicine 64(2): 99-106, 1997

Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents, including the new triazoles posaconazole, ravuconazole, and voriconazole. Journal of Clinical Microbiology 40(5): 1694-1697, 2002

The future of antifungal agents. Non azole antifungal agents. Nihon Ishinkin Gakkai Zasshi 40(3): 157-161, 1999

Azole antifungal agents. Clinical Infectious Diseases 14 Suppl 1: S161-S169, 1992

Second-generation azole antifungal agents. Drugs of Today 41(2): 91-105, 2005

Studies on antifungal agents. Part 25. 1--1H-1,2,4-triazoles. Helvetica Chimica Acta 71(7): 1622-1629, 1988

Synthesis of some new triazoles as potential antifungal agents. Bollettino Chimico Farmaceutico 140(6): 422-427, 2002

Azole derivatives of 1,4-benzothiazine as antifungal agents. Bioorganic & Medicinal Chemistry 6(1): 103-108, 1998